| __timestamp | Eli Lilly and Company | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4932500000 | 5758000 |
| Thursday, January 1, 2015 | 5037200000 | 8423000 |
| Friday, January 1, 2016 | 5654900000 | 11986000 |
| Sunday, January 1, 2017 | 6070200000 | 15215000 |
| Monday, January 1, 2018 | 4681700000 | 15356000 |
| Tuesday, January 1, 2019 | 4721200000 | 16660000 |
| Wednesday, January 1, 2020 | 5483300000 | 52459000 |
| Friday, January 1, 2021 | 7312800000 | 75061000 |
| Saturday, January 1, 2022 | 6629800000 | 87221000 |
| Sunday, January 1, 2023 | 7082200000 | 83779000 |
| Monday, January 1, 2024 | 8418299999 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Eli Lilly and Company compared to Supernus Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Eli Lilly consistently demonstrated a robust cost management strategy, with their cost of revenue peaking in 2021 at approximately 7.3 billion USD. This represents a 48% increase from their 2014 figures. In contrast, Supernus Pharmaceuticals, Inc. showed a more modest growth, with their cost of revenue increasing by over 1,400% during the same period, reaching around 87 million USD in 2022. This stark contrast highlights the scale and operational differences between the two companies. As the pharmaceutical industry continues to evolve, understanding these financial dynamics is crucial for investors and stakeholders alike.
Cost of Revenue Trends: Eli Lilly and Company vs AbbVie Inc.
Eli Lilly and Company vs Incyte Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Eli Lilly and Company and BioMarin Pharmaceutical Inc.
Breaking Down Revenue Trends: Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Comparison: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Key Insights on Gross Profit: Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Eli Lilly and Company and MiMedx Group, Inc.'s Expenses
Cost Insights: Breaking Down Johnson & Johnson and Supernus Pharmaceuticals, Inc.'s Expenses
Intra-Cellular Therapies, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and Supernus Pharmaceuticals, Inc.
Halozyme Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: PTC Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.